> top > docs > PMC:7544934 > spans > 133-1944 > annotations

PMC:7544934 / 133-1944 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T1 1377-1380 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T2 1377-1380 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN
T3 1489-1492 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T4 1489-1492 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN
T5 1539-1542 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T6 1539-1542 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN
T7 1698-1701 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T8 1698-1701 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 547-561 Phenotype denotes cytokine storm http://purl.obolibrary.org/obo/HP_0033041
T2 646-665 Phenotype denotes respiratory failure http://purl.obolibrary.org/obo/HP_0002878
T3 1010-1025 Phenotype denotes cytokines storm http://purl.obolibrary.org/obo/HP_0033041

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
30 440-470 Gene denotes Angiotensin-Converting Enzyme2 Gene:59272
31 472-476 Gene denotes ACE2 Gene:59272
32 757-763 Gene denotes ERK1/2 Gene:5595
33 809-815 Gene denotes ERK1/2 Gene:5595
34 958-963 Gene denotes Spike Gene:43740568
35 975-979 Gene denotes ACE2 Gene:59272
36 1036-1042 Gene denotes ERK1/2 Gene:5595
37 1413-1419 Gene denotes ERK1/2 Gene:5595
38 1524-1528 Gene denotes ACE2 Gene:59272
39 9-56 Species denotes Severe Acute Respiratory Syndrome Coronavirus 2 Tax:2697049
40 58-68 Species denotes SARS-CoV-2 Tax:2697049
41 256-269 Species denotes coronaviruses Tax:11118
42 271-281 Species denotes SARS-CoV-2 Tax:2697049
43 717-725 Species denotes patients Tax:9606
44 947-957 Species denotes SARS-CoV-2 Tax:2697049
45 1211-1221 Chemical denotes naltrexone MESH:D009271
46 1365-1375 Chemical denotes Naltrexone MESH:D009271
47 1708-1718 Chemical denotes naltrexone MESH:D009271
48 86-105 Disease denotes Coronavirus Disease MESH:D018352
49 107-115 Disease denotes COVID-19 MESH:C000657245
50 479-499 Disease denotes SARS-CoV-2 infection MESH:C000657245
51 646-665 Disease denotes respiratory failure MESH:D012131
52 682-704 Disease denotes multiple organ failure MESH:D009102
53 708-716 Disease denotes COVID-19 MESH:C000657245
54 1620-1641 Disease denotes coronavirus infection MESH:D018352
55 1652-1660 Disease denotes toxicity MESH:D064420

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T6 0-8 Sentence denotes Abstract
T7 9-156 Sentence denotes Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease (COVID-19) that has resulted in a global pandemic.
T8 157-244 Sentence denotes At the time of writing, approximately 16.06 million cases have been reported worldwide.
T9 245-478 Sentence denotes Like other coronaviruses, SARS-CoV-2 relies on the surface Spike glycoprotein to access the host cells, mainly through the interaction of its Receptor Binding Domain (RBD) with the host receptor Angiotensin-Converting Enzyme2 (ACE2).
T10 479-562 Sentence denotes SARS-CoV-2 infection induces a profound downstream pro-inflammatory cytokine storm.
T11 563-726 Sentence denotes This release of the pro-inflammatory cytokines is underpinning lung tissue damage, respiratory failure, and eventually multiple organ failure in COVID-19 patients.
T12 727-878 Sentence denotes The phosphorylation status of ERK1/2 is positively correlated with virus load and ERK1/2 inhibition suppressed viral replication and viral infectivity.
T13 879-1134 Sentence denotes Therefore, molecular entities able to interfere with binding of the SARS-CoV-2 Spike protein to ACE2, or damping hyperinflammatory cytokines storm, blocking ERK1/2 phosphorylation have a great potential to inhibit viral entry along with viral infectivity.
T14 1135-1345 Sentence denotes Herein, we report that the FDA-approved non-peptide opioid antagonist drug, naltrexone suppresses high fat/LPS induced pro-inflammatory cytokine release both from macrophage cells and Adipose Tissue Macrophage.
T15 1346-1430 Sentence denotes Moreover, Low Dose Naltrexone (LDN) also showed its activity as an ERK1/2 inhibitor.
T16 1431-1538 Sentence denotes Notably, virtual docking and simulation data also suggest LDN may disrupt the interaction of ACE2 with RBD.
T17 1539-1642 Sentence denotes LDN may be considered as a target as the treatment and (or) adjuvant therapy for coronavirus infection.
T18 1643-1776 Sentence denotes Clinical toxicity measurements may not be required for LDN since naltrexone was previously tested and is an approved drug by the FDA.
T19 1777-1805 Sentence denotes Communicated by Ramaswamy H.
T20 1806-1811 Sentence denotes Sarma